関節痛の世界市場レポート 2025年

関節痛市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.2％で77億3,000万米ドルに成長します。予測期間における成長の原動力は、関節痛に対する認知度の向上、高齢者人口の増加、ヘルスケアインフラの拡大、低侵襲治療に対する需要の高まり、スポーツ傷害の有病率の増加などが見込まれます。この時期の主な動向としては、デジタルヘルスソリューションの統合、新規療法や細胞療法の開発、医療技術の進歩、研究開発投資の増加などが挙げられます。

関節リウマチの罹患率の増加は、今後数年間の関節痛市場の成長を促進すると予想されます。関節リウマチは慢性的な自己免疫疾患で、主に関節に影響を与え、炎症、痛み、関節損傷の可能性を引き起こします。関節リウマチ患者の増加は、高齢化、遺伝的素因、ライフスタイルの変化、喫煙や汚染などの環境要因などの要因に起因しています。関節リウマチは、慢性的な関節の炎症を引き起こし、痛み、こわばり、進行性の損傷をもたらすことで、関節痛の一因となっています。例えば、2024年2月、オーストラリアを拠点とする非営利団体であるArthritis Australiaは、2040年までにオーストラリアにおける関節炎の患者数は2025年の411万人から539万人に増加し、関節リウマチの患者数は74万8,721人に達すると予測しています。その結果、関節リウマチ患者数の増加が関節痛市場の拡大に拍車をかけています。

関節痛市場の各社は、長期的な疼痛緩和と関節機能改善をもたらすRMAT指定遺伝子治療などの革新的治療法の開発に注力しています。RMAT指定遺伝子治療とは、FDAから再生医療先進治療（Regenerative Medicine Advanced Therapy：RMAT）の指定を受けた治療のことで、重篤な疾患や生命を脅かす疾患に対する遺伝子治療の開発と審査を加速させるものです。2024年3月、米国の製薬会社であるパシラ・バイオサイエンシズ社は、同社の製品PCRX-201（enekinragene inzadenovec）が米国食品医薬品局（FDA）からRMAT指定を受けた。PCRX-201は、インターロイキン-1受容体拮抗薬（IL-1Ra）を産生するヘルパー依存性アデノウイルス（HDAd）を用いて変形性膝関節症を治療するためにデザインされた革新的な関節内遺伝子治療薬候補です。パシラは、PCRX-201が変形性関節症の疾患修飾治療になる可能性を示唆する、有望な予備的臨床結果を強調しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界関節痛PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の関節痛市場：成長率分析
• 世界の関節痛市場の実績：規模と成長, 2019-2024
• 世界の関節痛市場の予測：規模と成長, 2024-2029, 2034F
• 世界関節痛総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の関節痛市場原因別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 変形性関節症
• 関節リウマチ
• 痛風
• 乾癬性関節炎
• ループス
• 怪我
• 感染症
• その他の原因
• 世界の関節痛市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医薬品
• 治療法
• 外科的介入
• ライフスタイルと家庭療法
• 世界の関節痛市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• トピック
• 経皮
• 世界の関節痛市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の関節痛市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ケア設定
• リハビリテーションセンター
• 世界の関節痛市場、変形性関節症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 変形性膝関節症
• 変形性股関節症
• 手の変形性関節症
• 脊椎変形性関節症
• 肩関節炎
• 世界の関節痛市場関節リウマチの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血清陽性関節リウマチ
• 血清陰性関節リウマチ
• 若年性関節リウマチ
• 早期発症型関節リウマチ
• 世界の関節痛市場痛風の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性痛風
• 二次性痛風
• 痛風性関節炎
• 世界の関節痛市場乾癬性関節炎の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 対称性乾癬性関節炎
• 非対称性乾癬性関節炎
• 乾癬性脊椎炎
• 遠位指節間優位型乾癬性関節炎
• 世界の関節痛市場ループスのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身性エリテマトーデス（SLE）
• 円板状エリテマトーデス
• 薬剤誘発性ループス
• 新生児ループス
• 世界の関節痛市場、傷害の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• スポーツ関連の怪我
• 外傷と骨折
• 捻挫と肉離れ
• 腱または靭帯の損傷
• 世界の関節痛市場感染症の種類別細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化膿性関節炎
• ウイルス性関節炎
• 細菌感染症
• 真菌感染症
• 世界の関節痛市場、その他の原因のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 線維筋痛症
• 使いすぎによる怪我
• サルコイドーシス
• 強直性脊椎炎
• 結晶誘発性関節炎

第7章 地域別・国別分析

• 世界の関節痛市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の関節痛市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 関節痛市場：競合情勢
• 関節痛市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• UCB S.A.
• Hikma Pharmaceuticals PLC
• Ferring Pharmaceuticals
• KD Pharma Group S.A.
• SI-BONE Inc.
• Xalud Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 関節痛市場2029：新たな機会を提供する国
• 関節痛市場2029：新たな機会を提供するセグメント
• 関節痛市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Arthralgia refers to pain in one or more joints, usually without inflammation, and can stem from various causes, including infections, autoimmune diseases, or injuries. It is a symptom rather than a standalone condition, often indicating an underlying health issue affecting the joints.

The primary causes of arthralgia include osteoarthritis, rheumatoid arthritis, gout, psoriatic arthritis, lupus, injuries, infections, and other contributing factors. Osteoarthritis is a degenerative joint disease that develops when the protective cartilage cushioning the ends of bones gradually wears down. A range of treatment options is available, including medications, therapies, surgical interventions, and lifestyle or home remedies. These treatments can be administered through different methods, such as oral, injectable, topical, and transdermal routes. They are distributed via hospital pharmacies, retail pharmacies, and online pharmacies and are used across various settings, including hospitals, clinics, home care environments, and rehabilitation centers.

The arthralgia market research report is one of a series of new reports from The Business Research Company that provides arthralgia market statistics, including the arthralgia industry global market size, regional shares, competitors with the arthralgia market share, detailed arthralgia market segments, market trends, and opportunities, and any further data you may need to thrive in the arthralgia industry. This arthralgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The arthralgia market size has grown strongly in recent years. It will grow from $5.20 billion in 2024 to $5.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the rising prevalence of autoimmune diseases, the increasing incidence of various associated risk factors, the growing rates of obesity, the higher prevalence of arthralgia, and the increasing occurrence of joint disorders.

The arthralgia market size is expected to see strong growth in the next few years. It will grow to $7.73 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period is expected to be driven by increasing awareness of arthralgia, a growing geriatric population, expanding healthcare infrastructure, rising demand for minimally invasive treatments, and the increasing prevalence of sports injuries. Key trends during this period include the integration of digital health solutions, the development of novel therapies and cell therapies, advancements in medical technology, and increased investment in research and development.

The increasing incidence of rheumatoid arthritis is expected to drive the growth of the arthralgia market in the coming years. Rheumatoid arthritis is a chronic autoimmune condition that primarily impacts the joints, causing inflammation, pain, and potential joint damage. The rise in rheumatoid arthritis cases can be attributed to factors such as an aging population, genetic predisposition, lifestyle changes, and environmental factors such as smoking and pollution. Rheumatoid arthritis contributes to arthralgia by causing chronic joint inflammation, leading to pain, stiffness, and progressive damage. For example, in February 2024, Arthritis Australia, a non-profit organization based in Australia, projected that by 2040, arthritis cases in Australia would increase to 5.39 million from 4.11 million in 2025, with rheumatoid arthritis cases reaching 748,721. Consequently, the growing number of rheumatoid arthritis cases is fueling the expansion of the arthralgia market.

Companies in the arthralgia market are focusing on developing innovative treatments, such as RMAT-designated gene therapies, to provide long-term pain relief and improved joint function. RMAT-designated gene therapy refers to a treatment that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which accelerates the development and review of gene therapies for serious or life-threatening conditions. In March 2024, Pacira BioSciences Inc., a US-based pharmaceutical company, received RMAT designation for its product PCRX-201 (enekinragene inzadenovec) from the U.S. Food and Drug Administration (FDA). PCRX-201 is an innovative intra-articular gene therapy candidate designed to treat knee osteoarthritis using a helper-dependent adenovirus (HDAd) to produce interleukin-1 receptor antagonists (IL-1Ra). Pacira emphasized the promising preliminary clinical results, suggesting that PCRX-201 could become a potential disease-modifying treatment for osteoarthritis.

In November 2023, Nevro Corp., a US-based medical device company, acquired Vyrsa Technologies for $75 million. This acquisition allows Nevro to expand its chronic pain treatment portfolio by incorporating Vyrsa Technologies' minimally invasive SI joint fusion devices. By enhancing its market presence, Nevro aims to provide advanced solutions for long-term pain relief to patients suffering from chronic sacroiliac (SI) joint pain. Vyrsa Technologies, a US-based company, specializes in treating arthralgia, specifically addressing chronic SI joint pain.

Major players in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation, and Vitazan Herbs and Vitamins Inc.

North America was the largest region in the arthralgia market in 2024. The regions covered in arthralgia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the arthralgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The arthralgia market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, physical rehabilitation programs, and supportive services. The market value includes the value of related goods sold by the service provider or included within the service offering. The arthralgia market also includes sales of musculoskeletal diagnostic tools, biologic drugs, anti-inflammatory drugs, and regenerative therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Arthralgia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on arthralgia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for arthralgia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The arthralgia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cause: Osteoarthritis; Rheumatoid Arthritis; Gout; Psoriatic Arthritis; Lupus; Injuries; Infections; Other Causes
• 2) By Treatment Type: Medications; Therapies; Surgical Interventions; Lifestyle And Home Remedies
• 3) By Route Of Administration: Oral; Injectable; Topical; Transdermal
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End User: Hospital; Clinics; Homecare Settings; Rehabilitation Centers
• Subsegments:
• 1) By Osteoarthritis: Knee Osteoarthritis; Hip Osteoarthritis; Hand Osteoarthritis; Spine Osteoarthritis; Shoulder Osteoarthritis
• 2) By Rheumatoid Arthritis: Seropositive Rheumatoid Arthritis; Seronegative Rheumatoid Arthritis; Juvenile Rheumatoid Arthritis; Early-Onset Rheumatoid Arthritis
• 3) By Gout: Primary Gout; Secondary Gout; Gouty Arthritis
• 4) By Psoriatic Arthritis: Symmetric Psoriatic Arthritis; Asymmetric Psoriatic Arthritis; Psoriatic Spondylitis; Distal Interphalangeal Predominant Psoriatic Arthritis
• 5) By Lupus: Systemic Lupus Erythematosus (SLE); Discoid Lupus Erythematosus; Drug-induced Lupus; Neonatal Lupus
• 6) By Injuries: Sports-related Injuries; Trauma and Fractures; Sprains and Strains; Tendon or Ligament Damage
• 7) By Infections: Septic Arthritis; Viral Arthritis; Bacterial Infections; Fungal Infections
• 8) By Other Causes: Fibromyalgia; Overuse Injuries; Sarcoidosis; Ankylosing Spondylitis; Crystal-induced Arthritis
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Sanofi S.A.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Arthralgia Market Characteristics

3. Arthralgia Market Trends And Strategies

4. Arthralgia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Arthralgia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Arthralgia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Arthralgia Market Growth Rate Analysis
• 5.4. Global Arthralgia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Arthralgia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Arthralgia Total Addressable Market (TAM)

6. Arthralgia Market Segmentation

• 6.1. Global Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Osteoarthritis
• Rheumatoid Arthritis
• Gout
• Psoriatic Arthritis
• Lupus
• Injuries
• Infections
• Other Causes
• 6.2. Global Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Therapies
• Surgical Interventions
• Lifestyle And Home Remedies
• 6.3. Global Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• Transdermal
• 6.4. Global Arthralgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Arthralgia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinics
• Homecare Settings
• Rehabilitation Centers
• 6.6. Global Arthralgia Market, Sub-Segmentation Of Osteoarthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand Osteoarthritis
• Spine Osteoarthritis
• Shoulder Osteoarthritis
• 6.7. Global Arthralgia Market, Sub-Segmentation Of Rheumatoid Arthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Seropositive Rheumatoid Arthritis
• Seronegative Rheumatoid Arthritis
• Juvenile Rheumatoid Arthritis
• Early-Onset Rheumatoid Arthritis
• 6.8. Global Arthralgia Market, Sub-Segmentation Of Gout, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Gout
• Secondary Gout
• Gouty Arthritis
• 6.9. Global Arthralgia Market, Sub-Segmentation Of Psoriatic Arthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symmetric Psoriatic Arthritis
• Asymmetric Psoriatic Arthritis
• Psoriatic Spondylitis
• Distal Interphalangeal Predominant Psoriatic Arthritis
• 6.10. Global Arthralgia Market, Sub-Segmentation Of Lupus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Lupus Erythematosus (SLE)
• Discoid Lupus Erythematosus
• Drug-induced Lupus
• Neonatal Lupus
• 6.11. Global Arthralgia Market, Sub-Segmentation Of Injuries, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sports-related Injuries
• Trauma and Fractures
• Sprains and Strains
• Tendon or Ligament Damage
• 6.12. Global Arthralgia Market, Sub-Segmentation Of Infections, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Septic Arthritis
• Viral Arthritis
• Bacterial Infections
• Fungal Infections
• 6.13. Global Arthralgia Market, Sub-Segmentation Of Other Causes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fibromyalgia
• Overuse Injuries
• Sarcoidosis
• Ankylosing Spondylitis
• Crystal-induced Arthritis

7. Arthralgia Market Regional And Country Analysis

• 7.1. Global Arthralgia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Arthralgia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Arthralgia Market

• 8.1. Asia-Pacific Arthralgia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Arthralgia Market

• 9.1. China Arthralgia Market Overview
• 9.2. China Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Arthralgia Market

• 10.1. India Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Arthralgia Market

• 11.1. Japan Arthralgia Market Overview
• 11.2. Japan Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Arthralgia Market

• 12.1. Australia Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Arthralgia Market

• 13.1. Indonesia Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Arthralgia Market

• 14.1. South Korea Arthralgia Market Overview
• 14.2. South Korea Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Arthralgia Market

• 15.1. Western Europe Arthralgia Market Overview
• 15.2. Western Europe Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Arthralgia Market

• 16.1. UK Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Arthralgia Market

• 17.1. Germany Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Arthralgia Market

• 18.1. France Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Arthralgia Market

• 19.1. Italy Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Arthralgia Market

• 20.1. Spain Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Arthralgia Market

• 21.1. Eastern Europe Arthralgia Market Overview
• 21.2. Eastern Europe Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Arthralgia Market

• 22.1. Russia Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Arthralgia Market

• 23.1. North America Arthralgia Market Overview
• 23.2. North America Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Arthralgia Market

• 24.1. USA Arthralgia Market Overview
• 24.2. USA Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Arthralgia Market

• 25.1. Canada Arthralgia Market Overview
• 25.2. Canada Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Arthralgia Market

• 26.1. South America Arthralgia Market Overview
• 26.2. South America Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Arthralgia Market

• 27.1. Brazil Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Arthralgia Market

• 28.1. Middle East Arthralgia Market Overview
• 28.2. Middle East Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Arthralgia Market

• 29.1. Africa Arthralgia Market Overview
• 29.2. Africa Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Arthralgia Market Competitive Landscape And Company Profiles

• 30.1. Arthralgia Market Competitive Landscape
• 30.2. Arthralgia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Arthralgia Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline PLC
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Astellas Pharma Inc.
• 31.9. Biogen Inc.
• 31.10. UCB S.A.
• 31.11. Hikma Pharmaceuticals PLC
• 31.12. Ferring Pharmaceuticals
• 31.13. KD Pharma Group S.A.
• 31.14. SI-BONE Inc.
• 31.15. Xalud Therapeutics Inc.

32. Global Arthralgia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Arthralgia Market

34. Recent Developments In The Arthralgia Market

35. Arthralgia Market High Potential Countries, Segments and Strategies

• 35.1 Arthralgia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Arthralgia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Arthralgia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer